pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 66
- Patents
- 0
Live attenuated Japanese encephalitis chimeric virus vaccine
Phase 3 · mab · Japanese Encephalitis
Live attenuated Japanese encephalitis chimeric virus vaccine for Japanese Encephalitis is a Phase 3 program (mab) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code JEC12
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Phase 3
- Modality
- mab
- Indication
- Japanese Encephalitis
- Status
- completed
- Trials
- 1